11.09.26 -- Critical Decisions Driving Next-Generation Cell Line Development

As MSC therapies move from autologous to allogeneic use and higher cell doses, the question shifts from efficacy to reliable expansion. See how design, closed handling, and media shape scale-up.

Consistent, contamination-free sampling is critical for reliable bioprocess data. Automation enables frequent, hands-free collection, improving efficiency and insight while reducing manual workload.

Delve into how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.

Explore a scalable protocol for T cell activation and expansion, designed to enhance workflows. This approach ensures robust T cell growth, viability, and memory phenotypes for applications. 

Discover closed, automated harvest, formulation, and dispensing of umbilical cord MSCs at commercial scale, with data on viability, recovery, and filling precision, including single runs.

An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

Learn about electroporation technology that has been found to improve transfection efficiency and cell viability significantly, without requiring specific expression constructs or specialized reagents.

Uncover how Synthego's proprietary synthetic sgRNA, combined with Lonza’s 4D-Nucleofector®, enabled highly efficient gene editing in resting human CD4+ T cells.

Expression often limits antibody discovery because functional screening needs soluble, correctly folded protein. Explore how moving expression into screening changes which candidates get tested.

Gain insight into how digital standardized tools can streamline your scaling processes and enable more accurate prediction and visualization of your scaling needs.

Examine how CD137-based enrichment improves glioblastoma TIL manufacturing by expanding reactive T cell populations, preserving unique clonotypes, and strengthening autologous tumor cell killing.

Watch how targeted media supplementation can improve CHO cell culture outcomes, simplify process optimization, and increase productivity across monoclonal antibodies and emerging modalities.